Skip to main content
Log in

AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167: 4686–4692.

    Article  CAS  Google Scholar 

  2. Martin C, Bridger GJ, Rankin SM . Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 2006; 134: 326–329.

    Article  CAS  Google Scholar 

  3. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  Google Scholar 

  4. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904–1912.

    Article  CAS  Google Scholar 

  5. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  Google Scholar 

  6. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.

    Article  CAS  Google Scholar 

  7. Xu H, Exner BG, Chilton PM, Tanner MK, Mueller YM, Rezzoug F et al. A delay in bone marrow transplantation after partial conditioning improves engraftment. Transplantation 2004; 77: 819–826.

    Article  Google Scholar 

  8. Xun C, Tsuchida M, Thompson J . Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297–302.

    Article  CAS  Google Scholar 

  9. Yunchuan D, Rotta M, Graves S, Storer B, Peterson LJ, Sale G et al. Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2009; 15: 1244–1250.

    Article  Google Scholar 

  10. Guidance to Accompany the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration, 4th edn. FACT Accreditation Office: Omaha, NE, USA; JACIE Accreditation Office: Barcelona, Spain, 2010 p. 89.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G Milone.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leotta, S., Poidomani, M., Mauro, E. et al. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant 46, 314–316 (2011). https://doi.org/10.1038/bmt.2010.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.98

  • Springer Nature Limited

This article is cited by

Navigation